vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and FORRESTER RESEARCH, INC. (FORR). Click either name above to swap in a different company.
FORRESTER RESEARCH, INC. is the larger business by last-quarter revenue ($101.1M vs $83.5M, roughly 1.2× BillionToOne, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -33.5%, a 40.4% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs -6.5%). BillionToOne, Inc. produced more free cash flow last quarter ($6.5M vs $-4.3M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Forrester Research, Inc. is a research and advisory firm working in research, consulting and events. Forrester’s clients include large global business, technology and consumer enterprises. The firm is headquartered in Cambridge, MA.
BLLN vs FORR — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $101.1M |
| Net Profit | $5.7M | $-33.9M |
| Gross Margin | 69.9% | 56.7% |
| Operating Margin | 11.5% | -36.6% |
| Net Margin | 6.8% | -33.5% |
| Revenue YoY | 117.4% | -6.5% |
| Net Profit YoY | 138.3% | -7941.4% |
| EPS (diluted) | $0.10 | $-1.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $101.1M | ||
| Q3 25 | $83.5M | $94.3M | ||
| Q2 25 | — | $111.7M | ||
| Q1 25 | — | $89.9M | ||
| Q4 24 | — | $108.0M | ||
| Q3 24 | $38.4M | $102.5M | ||
| Q2 24 | — | $121.8M | ||
| Q1 24 | — | $100.1M |
| Q4 25 | — | $-33.9M | ||
| Q3 25 | $5.7M | $-2.1M | ||
| Q2 25 | — | $3.9M | ||
| Q1 25 | — | $-87.3M | ||
| Q4 24 | — | $432.0K | ||
| Q3 24 | $-14.9M | $-5.8M | ||
| Q2 24 | — | $6.3M | ||
| Q1 24 | — | $-6.7M |
| Q4 25 | — | 56.7% | ||
| Q3 25 | 69.9% | 60.0% | ||
| Q2 25 | — | 55.5% | ||
| Q1 25 | — | 55.9% | ||
| Q4 24 | — | 58.8% | ||
| Q3 24 | 52.6% | 60.5% | ||
| Q2 24 | — | 57.3% | ||
| Q1 24 | — | 54.9% |
| Q4 25 | — | -36.6% | ||
| Q3 25 | 11.5% | 4.7% | ||
| Q2 25 | — | 6.2% | ||
| Q1 25 | — | -97.5% | ||
| Q4 24 | — | -0.5% | ||
| Q3 24 | -32.9% | -0.7% | ||
| Q2 24 | — | 9.3% | ||
| Q1 24 | — | -9.3% |
| Q4 25 | — | -33.5% | ||
| Q3 25 | 6.8% | -2.3% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | -97.1% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | -38.8% | -5.7% | ||
| Q2 24 | — | 5.2% | ||
| Q1 24 | — | -6.7% |
| Q4 25 | — | $-1.75 | ||
| Q3 25 | $0.10 | $-0.11 | ||
| Q2 25 | — | $0.20 | ||
| Q1 25 | — | $-4.62 | ||
| Q4 24 | — | $0.02 | ||
| Q3 24 | $-1.47 | $-0.30 | ||
| Q2 24 | — | $0.33 | ||
| Q1 24 | — | $-0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $63.3M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $126.5M |
| Total Assets | $327.5M | $404.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $63.3M | ||
| Q3 25 | $195.2M | $65.1M | ||
| Q2 25 | — | $67.8M | ||
| Q1 25 | — | $75.6M | ||
| Q4 24 | — | $56.1M | ||
| Q3 24 | — | $62.8M | ||
| Q2 24 | — | $58.9M | ||
| Q1 24 | — | $61.4M |
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $126.5M | ||
| Q3 25 | $-239.5M | $157.7M | ||
| Q2 25 | — | $159.5M | ||
| Q1 25 | — | $147.4M | ||
| Q4 24 | — | $229.5M | ||
| Q3 24 | $-242.9M | $234.3M | ||
| Q2 24 | — | $237.1M | ||
| Q1 24 | — | $230.9M |
| Q4 25 | — | $404.0M | ||
| Q3 25 | $327.5M | $414.2M | ||
| Q2 25 | — | $436.0M | ||
| Q1 25 | — | $439.8M | ||
| Q4 24 | — | $503.9M | ||
| Q3 24 | — | $505.3M | ||
| Q2 24 | — | $524.2M | ||
| Q1 24 | — | $555.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $-3.2M |
| Free Cash FlowOCF − Capex | $6.5M | $-4.3M |
| FCF MarginFCF / Revenue | 7.7% | -4.2% |
| Capex IntensityCapex / Revenue | 8.8% | 1.1% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $18.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-3.2M | ||
| Q3 25 | $13.8M | $1.2M | ||
| Q2 25 | — | $-3.6M | ||
| Q1 25 | — | $26.7M | ||
| Q4 24 | — | $-1.8M | ||
| Q3 24 | — | $264.0K | ||
| Q2 24 | — | $-2.9M | ||
| Q1 24 | — | $611.0K |
| Q4 25 | — | $-4.3M | ||
| Q3 25 | $6.5M | $524.0K | ||
| Q2 25 | — | $-4.2M | ||
| Q1 25 | — | $26.1M | ||
| Q4 24 | — | $-2.5M | ||
| Q3 24 | — | $-223.0K | ||
| Q2 24 | — | $-3.7M | ||
| Q1 24 | — | $-815.0K |
| Q4 25 | — | -4.2% | ||
| Q3 25 | 7.7% | 0.6% | ||
| Q2 25 | — | -3.8% | ||
| Q1 25 | — | 29.0% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | -0.2% | ||
| Q2 24 | — | -3.1% | ||
| Q1 24 | — | -0.8% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | 8.8% | 0.7% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | -0.93× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -4.24× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.46× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
